175 related articles for article (PubMed ID: 31554639)
1. IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells.
Toyoshima Y; Kitamura H; Xiang H; Ohno Y; Homma S; Kawamura H; Takahashi N; Kamiyama T; Tanino M; Taketomi A
Cancer Immunol Res; 2019 Dec; 7(12):1944-1957. PubMed ID: 31554639
[TBL] [Abstract][Full Text] [Related]
2. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
3. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
Li J; Xu J; Yan X; Jin K; Li W; Zhang R
Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
[TBL] [Abstract][Full Text] [Related]
4. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H
Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799
[TBL] [Abstract][Full Text] [Related]
5. The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies.
Rolvering C; Zimmer AD; Ginolhac A; Margue C; Kirchmeyer M; Servais F; Hermanns HM; Hergovits S; Nazarov PV; Nicot N; Kreis S; Haan S; Behrmann I; Haan C
J Leukoc Biol; 2018 Nov; 104(5):969-985. PubMed ID: 30040142
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt SL; Bailey D; Zielinski J; Apte A; Musenge F; Karp R; Burke S; Garcon F; Mishra A; Gurumurthy S; Watkins A; Arnold K; Moynihan J; Clancy-Thompson E; Mulgrew K; Adjei G; Deschler K; Potz D; Moody G; Leinster DA; Novick S; Sulikowski M; Bagnall C; Martin P; Lapointe JM; Si H; Morehouse C; Sedic M; Wilkinson RW; Herbst R; Frederick JP; Luheshi N
Clin Cancer Res; 2020 Dec; 26(23):6284-6298. PubMed ID: 32817076
[TBL] [Abstract][Full Text] [Related]
7. IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung.
Jing B; Wang T; Sun B; Xu J; Xu D; Liao Y; Song H; Guo W; Li K; Hu M; Zhang S; Ling J; Kuang Y; Zhang T; Zhou BP; Yao F; Deng J
Cancer Res; 2020 Feb; 80(4):784-797. PubMed ID: 31848193
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer.
Chen X; Xu J; Guo Q; Wang L; Yang Y; Guo H; Gu N; Zhang D; Qian W; Hou S; Li J; Dai J; Guo Y; Wang H
Biochem Biophys Res Commun; 2016 Nov; 480(2):160-165. PubMed ID: 27720718
[TBL] [Abstract][Full Text] [Related]
9. RORγt-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells.
Rizzo A; Di Giovangiulio M; Stolfi C; Franzè E; Fehling HJ; Carsetti R; Giorda E; Colantoni A; Ortenzi A; Rugge M; Mescoli C; Monteleone G; Fantini MC
Cancer Immunol Res; 2018 Sep; 6(9):1082-1092. PubMed ID: 29991500
[TBL] [Abstract][Full Text] [Related]
10. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
11. Stromal Cell PD-L1 Inhibits CD8
O'Malley G; Treacy O; Lynch K; Naicker SD; Leonard NA; Lohan P; Dunne PD; Ritter T; Egan LJ; Ryan AE
Cancer Immunol Res; 2018 Nov; 6(11):1426-1441. PubMed ID: 30228206
[TBL] [Abstract][Full Text] [Related]
12. TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression.
Nakamura S; Yaguchi T; Kawamura N; Kobayashi A; Sakurai T; Higuchi H; Takaishi H; Hibi T; Kawakami Y
J Immunother; 2014; 37(2):63-72. PubMed ID: 24509168
[TBL] [Abstract][Full Text] [Related]
13. The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6.
Yin Y; Yao S; Hu Y; Feng Y; Li M; Bian Z; Zhang J; Qin Y; Qi X; Zhou L; Fei B; Zou J; Hua D; Huang Z
Clin Cancer Res; 2017 Dec; 23(23):7375-7387. PubMed ID: 28928161
[No Abstract] [Full Text] [Related]
14. Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.
Liu X; Zhou Z; Cheng Q; Wang H; Cao H; Xu Q; Tuo Y; Jiang L; Zou Y; Ren H; Xiang M
Cell Death Dis; 2017 Sep; 8(9):e3033. PubMed ID: 28880262
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles and function of IL6 in polymorphonuclear myeloid-derived suppressor cells.
Ibrahim ML; Lu C; Klement JD; Redd PS; Yang D; Smith AD; Liu K
Cancer Immunol Immunother; 2020 Nov; 69(11):2233-2245. PubMed ID: 32488308
[TBL] [Abstract][Full Text] [Related]
16. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
17. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
18. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
19. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis.
Zhang Y; Davis C; Shah S; Hughes D; Ryan JC; Altomare D; Peña MM
Mol Carcinog; 2017 Jan; 56(1):272-287. PubMed ID: 27120577
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
